Entity

Time filter

Source Type

Bardstown, KY, United States

Sullivan University is licensed to offer bachelor's, master's and doctoral degrees by the Kentucky Council on Postsecondary Education in accordance with the provisions of KRS 164.945-164.99, based in Louisville, Kentucky and is accredited by the Southern Association of Colleges and Schools—the first for-profit college or university to receive this accreditation. Sullivan University currently has physical campuses in Louisville, Lexington, and Fort Knox, and an online campus. With approximately 6,000 students, Sullivan is Kentucky's largest private university. Wikipedia.


Prasad-Reddy L.,Sullivan University
U.S. Pharmacist | Year: 2012

It is estimated that 14% of girls and 7% of boys aged 9 to 14 years exhibit behavioral patterns reflective of eating disorders. The Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV), further divides eating disorders into three distinct diagnoses-anorexia, bulimia, and eating disorder not otherwise specified-??based on clinical characteristics, behavioral patterns, and symptoms. Unfortunately, many individuals exhibiting disordered eating patterns fail to seek appropriate treatment, leading to a multitude of complications affecting all organ systems. As a result, eating disorders carry the highest mortality rate-??approaching 20%-??of all psychiatric illnesses. Young adults with diabetes are at increased risk for developing psychiatric comorbidities, including eating disorders, because of the complex nature of chronic disease management as well as the effects of chronic disease on psychosocial functioning. The presence of psychiatric comorbidity can lead to suboptimal glycemic management and disease.4This article will discuss the dynamic nature of eating disorders in type 1 diabetes mellitus (T1DM) patients, including clinical features, consequences, and management. Source


BACKGROUND: Recent changes in the United States (US) economy have radically disrupted revenue generation among many institutions within higher education within the US. Chief among these disruptions has been fallout associated with the financial crisis of 2008-2009, which triggered a change in the US higher education environment from a period of relative munificence to a prolonged period of scarcity. The hardest hit by this disruption have been smaller, less wealthy institutions which tend to lack the necessary reserves to financially weather the economic storm. Interestingly, a review of institutional effectiveness among these institutions revealed that while many are struggling, some institutions have found ways to not only successfully cope with the impact of declining revenue, but have been able to capitalize on the disruption and thrive. OBJECTIVE: Organizational response is an important factor in successfully coping with conditions of organizational decline. The study examined the impacts of organizational response on institutional effectiveness among higher education institutions experiencing organizational decline. The study's research question asked why some US higher educational institutions are more resilient at coping with organizational decline than other institutions operating within the same segment of the higher education sector. More specifically, what role does organizational resilience have in helping smaller, private non-profit institutions cope and remain effective during organizational decline? PARTICIPANTS: A total of 141 US smaller, private non-profit higher educational institutions participated in the study; specifically, the study included responses from participant institutions' key administrators. METHODS: 60-item survey evaluated administrator responses corresponding to organizational response and institutional effectiveness. Factor analysis was used to specify the underlying structures of rigidity response, resilience response, and institutional effectiveness. Multiple regression analysis was used to examine the direct and interaction effects between organizational decline, organizational rigidity response, organizational resilience response, and institutional effectiveness, controlling for age of institution and level of endowment. RESULTS: The study validated previous threat-rigidity response findings that organizational decline alone does not adversely impact institutional effectiveness. The direct effect of Goal-Directed Solution Seeking and Role Dependency organizational resilience factors had a positive, significant correlation with the Student Personal Development institutional effectiveness factor. The interactive effect of Goal-Directed Solution Seeking organizational resilience factor during organizational decline had a positive, significant correlation with the Professional Development and Quality of Faculty institutional effectiveness factor. The interactive effect of Avoidance during organizational decline had a positive, significant correlation with the Faculty and Administrator Employment Satisfaction institutional effectiveness factor. The interactive effect of Diminished Innovation, Morale, and Leader Credibility rigidity response factor and Avoidance organizational resilience factor during organizational decline had a positive, significant correlation with the Professional Development and Quality of Faculty institutional effectiveness factor. Lastly, the interactive effect of Increased Scapegoating of Leaders, Interest group Activities, and Conflict rigidity response factor and Avoidance organizational resilience factor during organizational decline had a positive, significant correlation with the Faculty and Administrator Employment Satisfaction institutional effectiveness factor. CONCLUSIONS: Factors of organizational resilience were found to have a positive effect among smaller, private non-profit higher educational institutions associated with this study toward sustaining institutional effectiveness during organizational decline. Specifically, the organizational resilience factors of Goal-Directed Solution Seeking (i.e., mission-driven solutions) and Avoidance (i.e., skepticism toward new ideas) play a significant, collaborative role among smaller, private non-profit higher educational institutions when it comes to sustaining institutional effectiveness during organizational decline. © 2016 - IOS Press and the authors. Source


Coulter C.J.,Sullivan University | Montandon S.V.,University of Louisville
Pharmacotherapy | Year: 2012

Clopidogrel is an oral thienopyridine that has been shown to reduce the risk of vascular death in patients with acute coronary syndrome, ischemic stroke, and peripheral vascular disease. The drug is associated with rare adverse effects such as thrombotic thrombocytopenia purpura, acute hepatotoxicity, and neutropenia. Only six cases have been reported that link acute arthritis with the use of clopidogrel. We describe a 64-year-old Caucasian man with sudden onset of severe arthritis, erythema, and swelling after starting clopidogrel therapy; he had no history of arthralgias while taking prasugrel during the previous 8 months. The patient was hospitalized for 3 days, and after cessation of clopidogrel therapy and conservative management, he improved dramatically, showing resolution of his joint erythema and swelling. The patient started prasugrel therapy at discharge, and no arthritic development was noted 8 weeks later. Although clopidogrel is commonly well tolerated, this case report demonstrates that clinicians should be aware that acute arthritis may be a possible adverse effect of clopidogrel. Additionally, polyarthralgias may not be a class effect of thienopyridines; patients who experience acute arthralgias during clopidogrel therapy may not experience similar adverse effects with prasugrel. Copyright © 1999-2012 John Wiley & Sons, Inc. Source


Palmer E.C.,Sullivan University | Binns L.N.,Southern Arizona Veterans Affairs Healthcare System | Carey H.,Louis Stokes Cleveland Veterans Affairs Medical Center
Annals of Pharmacotherapy | Year: 2014

Objective: To provide a clinical overview of the antidepressant levomilnacipran. Data Sources: Articles were identified by searching the MEDLINE, PubMed, Cochrane Library, and Clinicaltrials.gov databases through March 2014 using the keyword levomilnacipran. The manufacturer provided additional information from unpublished phase II and phase III trials. Study Selection and Data Extraction: Any clinical trial conducted for at least 3 weeks and published in the English language was selected for review. Additional documentation, including the product dossier, package insert, pharmacokinetic studies, and poster presentations supplied by the manufacturer, was also evaluated. Data Synthesis: Levomilnacipran is the more potent enantiomer of milnacipran. It is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), dosed from 20 to 120 mg daily for the treatment of major depressive disorder (MDD). Efficacy and tolerability were established during 3 phase III randomized, double-blind placebo-controlled trials finding levomilnacipran to be significantly more efficacious than placebo in reduction of Montgomery-Åsberg Depression Rating Scale scores. It is not known whether this agent is more efficacious than other antidepressants because direct comparison studies have not been conducted as of the time of this review. Conclusions: Levomilnacipran demonstrates efficacy and tolerability for short-term treatment of MDD in adults. Available evidence does not strongly indicate that there is a specific subpopulation of patients who would benefit from levomilnacipran over currently available SNRIs. Full characterization of the agent's place in therapy alongside multiple other agents with similar mechanisms and efficacy requires trials with longer duration and active comparators. © The Author(s) 2014. Source


Griffin A.T.,University of Louisville | Harting J.A.,University of Louisville | Harting J.A.,Sullivan University | Christensen D.M.,University of Louisville
Diagnostic Microbiology and Infectious Disease | Year: 2013

Tigecycline is approved for cutaneous infections, intra-abdominal infections, and community-acquired pneumonia. However, pharmacokinetic data suggest therapeutic concentrations in additional sites, such as bone, despite exiguous clinical data supporting such use. Thus, the objective of this study was to analyze patients with osteomyelitis treated with tigecycline to ascertain its utility in this malady. Our database of osteomyelitis patients was surveyed for instances treated with tigecycline. Cases were evaluated in terms of adverse events and clinical success. Nineteen patients received tigecycline for osteomyelitis. Thirteen met criteria for evaluation of the primary endpoint of clinical success. The most common dose employed was 50 mg twice daily. Adverse events, however, were not statistically more likely with 100 mg administered once daily. Eleven patients (85%) achieved clinical success. Thus, congruent with pharmacokinetic data, tigecycline appeared efficacious for osteomyelitis in the majority of patients who received it. Adverse events were not correlated with dosing strategy. © 2013 Elsevier Inc. Source

Discover hidden collaborations